Bill & Melinda Gates Foundation announces 'COVID-19 Therapeutics Accelerator' to accelerate development of therapeutics for new coronavirus infectious diseases with funds of over 13 billion yen



The

Bill & Melinda Gates Foundation is the world's largest charity fund founded by Microsoft founder Bill Gates with his wife Melinda. The foundation has announced the COVID-19 Therapeutics Accelerator, an initiative to accelerate the development of therapeutics for new coronavirus infections (COVID-19). The Bill & Melinda Gates Foundation, along with Wellcome and Mastercard , will invest up to $ 125 million to speed up the response to COVID-19.

Announcing the COVID-19 Therapeutics Accelerator-Bill & Melinda Gates Foundation
https://www.gatesfoundation.org/TheOptimist/Articles/coronavirus-mark-suzman-therapeutics

Bill & Melinda Gates Foundation, Wellcome, and Mastercard Launch Initiative to Speed Development and Access to Therapies for COVID-19-Bill & Melinda Gates Foundation
https://www.gatesfoundation.org/Media-Center/Press-Releases/2020/03/COVID-19-Therapeutics-Accelerator

The COVID-19 Therapeutics Accelerator, announced by the Bill & Melinda Gates Foundation, will accelerate and evaluate the development of new and existing drugs and biologicals, and in the short term, In the long term, the aim is to treat other viral pathogens. At the time of writing, there are no antiviral drugs or immunotherapy available for COVID-19.



The Bill & Melinda Gates Foundation and Wellcome each contribute up to $ 50 million, and the Mastercard Impact Fund contributes up to $ 25 million, supporting the COVID-19 Therapeutics Accelerator. The Bill & Melinda Gates Foundation had

announced that it would provide up to $ 100 million (approximately 10 billion yen) for COVID-19 countermeasures, but $ 50 million provided to COVID-19 Therapeutics Accelerator Is also part of it.

'While COVID-19 has spread rapidly, the development of vaccines and therapies to stop it has progressed slowly. Like COVID-19,' said Mark Suzeman, CEO of the Bill & Melinda Gates Foundation. If you want to protect the world from harm, you need to find ways to accelerate research and development, even for the most vulnerable, because governments, private companies, and charities act quickly. And fund research and development, 'he explains why he launched the COVID-19 Therapeutics Accelerator.



The COVID-19 Therapeutics Accelerator works with the

World Health Organization (WHO), government and private sector funders and organizations, and global regulatory and policy setting bodies. Furthermore, in the development of therapeutic drugs for COVID-19, it will provide end-to-end support from development of the development pipeline to production and scale-up. According to the Bill & Melinda Gates Foundation, 'By providing rapid and flexible funding at key stages of the development process, the COVID-19 Therapeutics Accelerator will provide new medicines and biology for COVID-19 and potential future epidemics. We will reduce the risk of developing generic formulations and make them available in resource-poor countries. '

The COVID-19 Therapeutics Accelerator explores several aspects of the therapeutic drug development cycle and streamlines the path to clinical evaluation, use, and manufacture of drug candidates. To identify potential therapeutic compounds, the COVID-19 Therapeutics Accelerator `` tests already approved drugs '' for activity against COVID-19 and uses a library of thousands of compounds using safety data. , Screening new compounds, and testing new compounds and examining monoclonal antibodies .

The biotechnology and pharmaceutical industries will be key partners of the COVID-19 Therapeutics Accelerator, leveraging compound libraries and clinical data to provide the expertise needed to scale up existing drugs and monoclonal antibodies. In addition, the COVID-19 Therapeutics Accelerator will work with regulators to adjust standards for COVID-19 and develop manufacturing capacity throughout the industry.

The timeline for bringing effective treatment to patients is approximately one year for products that have received regulatory approval at the time of writing or have candidate data with existing clinical data. However, for compounds with limited existing clinical data or in the early stages of development, the time to actual use is longer.



`` The new coronavirus (SARS-CoV-2) is an unprecedented global threat, and we have formed an international partnership to develop treatments, rapid diagnosis, and vaccines, '' said Wellcome Director Jeremy Farrer. We have to move forward, science is moving at a phenomenal pace against COVID-19, but we need to make more investments and coordinate research to stay ahead of the epidemic. ' Talking.

`` We are proud to be part of this important initiative to fight COVID-19, '' said Mike Fromman, Vice Chairman of Mastercard. 'This global challenge is not the very risk to the health and safety of people around the world. But it also has the potential to disrupt the economic vitality of millions of people, businesses and organizations around the world, 'stressed the importance of the COVID-19 Therapeutics Accelerator.

Related Posts:

in Note, Posted by logu_ii